Seattle Genetics Appoints Robin Taylor, Ph.D., Chief Commercial Officer
May 21 2019 - 8:00AM
Business Wire
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the
appointment of Robin G. Taylor, M.B.A., Ph.D., as Chief Commercial
Officer. Dr. Taylor brings 18 years of biotechnology and
pharmaceutical company experience in the commercialization of
oncology drugs, including significant marketing, launch and global
product strategy roles at both Genentech/Roche and AstraZeneca. He
contributed to several leading global brands, including TECENTRIQ®
(atezolizumab), ALECENSA® (alectinib), AVASTIN® (bevacizumab) and
HERCEPTIN® (trastuzumab).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190521005064/en/
Robin G. Taylor, M.B.A., Ph.D., Chief
Commercial Officer at Seattle Genetics (Photo: Business Wire)
Clay Siegall, Ph.D., President and Chief Executive Officer of
Seattle Genetics, commented, “We are excited to welcome Robin to
the executive management team as our first Chief Commercial
Officer. He has demonstrated strong leadership and success in the
global commercial development and strategic marketing of several
oncology franchises, notably at Genentech/Roche. Robin will play a
key role in extending our commercial execution across six ADCETRIS
lymphoma indications, while preparing for the potential launch of
enfortumab vedotin and leading our global commercialization
strategy for possible future products, such as tucatinib.”
Dr. Taylor stated, “Seattle Genetics has an outstanding culture
of innovation and scientific excellence with a broad late-stage
pipeline focused on providing a significant benefit to cancer
patients with high unmet need. I look forward to leading the
Commercial organization to bring these exciting therapies to
patients as the company transitions to a multi-product, global
oncology company.”
Robin Taylor has extensive global development and
commercialization oncology experience. Most recently, he served as
Vice President, Immuno-Oncology Franchise Head, Oncology Business
Unit at AstraZeneca, where he led global marketing and product
teams for IMFINZI® (durvalumab), an immunotherapy approved for
metastatic urothelial carcinoma, and Stage III unresectable
non-small cell lung cancer. Prior to joining AstraZeneca, Dr.
Taylor served in roles of increasing responsibility at Genentech, a
Member of the Roche Group, from 2001 to 2018. Most recently, he
served as Vice President, Cancer Immunotherapy Franchise Head,
Global Product Strategy, responsible for the global development and
launch of TECENTRIQ across multiple indications. He received a
Doctor of Philosophy, Molecular and Medical Genetics from
University of Toronto, a Masters of Business Administration from
University of California Berkeley, and a Bachelor of Science degree
from University of British Columbia.
About Seattle Genetics
Seattle Genetics, Inc. is an emerging multi-product, global
biotechnology company that develops and commercializes
transformative therapies targeting cancer to make a meaningful
difference in people’s lives. ADCETRIS® (brentuximab vedotin)
utilizes the company’s industry-leading ADC technology and is
currently approved for the treatment of multiple CD30-expressing
lymphomas. Beyond ADCETRIS, the company has established a pipeline
of novel targeted therapies at various stages of clinical testing,
including three in ongoing pivotal trials for solid tumors.
Enfortumab vedotin for metastatic urothelial cancer and tisotumab
vedotin for metastatic cervical cancer utilize our proprietary ADC
technology. Tucatinib, a small molecule tyrosine kinase inhibitor,
is in a pivotal trial for HER2-positive metastatic breast cancer.
In addition, we are leveraging our expertise in empowered
antibodies to build a portfolio of proprietary immuno-oncology
agents in clinical trials targeting hematologic malignancies and
solid tumors. The company is headquartered in Bothell, Washington,
and has a European office in Switzerland. For more information on
our robust pipeline, visit www.seattlegenetics.com and follow
@SeattleGenetics on Twitter.
Forward-Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the company’s
transition into a multi-product global oncology company,
expectations regarding expansion of the commercial uses of ADCETRIS
and advancement of the company’s late-stage oncology pipeline,
including enfortumab vedotin, tisotumab vedotin and tucatinib and
the company’s other product candidates and those of its licensees
and collaborators; as well as other statements that are not
historical facts. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with maintaining or increasing
sales of ADCETRIS due to competition, unexpected adverse events,
regulatory action, reimbursement, market adoption by physicians or
other factors. The company may also be delayed in its planned
clinical trial initiations, the enrollment in and conduct of its
clinical trials, obtaining data from clinical trials, planned
regulatory submissions, and regulatory approvals in each case for a
variety of reasons including the difficulty and uncertainty of
pharmaceutical product development, negative or disappointing
clinical trial results, unexpected adverse events or regulatory
discussions or actions and the inherent uncertainty associated with
the regulatory approval process. More information about the risks
and uncertainties faced by Seattle Genetics is contained
under the caption “Risk Factors” in the Company’s Quarterly Report
on Form 10-Q for the quarter ended March 31, 2019 filed with
the Securities and Exchange Commission. Seattle
Genetics disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise except as required by
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190521005064/en/
Media:Monique Greer(425) 527-4641mgreer@seagen.com
Investors:Peggy Pinkston(425) 527-4160ppinkston@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024